Juno Therapeutics Obtains $31,000,000 Series A Financing

  • Feed Type
  • Date
    4/24/2014
  • Company Name
    Juno Therapeutics
  • Mailing Address
    307 Westlake Avenue North Seattle, WA 98109 USA
  • Company Description
    Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies.
  • Website
    http://www.junotherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $31,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Juno’s initial funding of $120 million came predominantly from leading technology venture capital firm ARCH Venture Partners and the Alaska Permanent Fund, through a partnership managed by Crestline Investors. The completion of the A round includes expansions from founding investors as well as investments from Bezos Expeditions, the personal investment company of Jeff Bezos, and Venrock, amongst others.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor

By posting a comment, you agree to our terms and conditions.